The Trump Administration Is Waiving the Public’s Right to Affordable Coronavirus Treatments

Gilead Sciences announced its Covid-19 therapy drug, remdesivir, will cost private insurers $520 for a single vial, hundreds of times its production cost, which researchers have estimated at 93 cents per dose.

Standard federal contracts ensure that inventions developed with government funding are available to the public “on reasonable terms.” But the four agreements for Covid-19-related products — three of which were made by a division of the Department of Health and Human Services known as the Biomedical Advanced Research and Development Authority, or BARDA, and one of which was made with the Department of Defense — notably omitted the phrase “on reasonable terms.” The government contracts with pharmaceutical companies Janssen, Regeneron, Genentech, and Ology Bioservices also limit the government’s patent rights to the products being developed for Covid-19, even though they are using taxpayer dollars to do so.

The details of the contracts, which were released to the nonprofit advocacy group Knowledge Ecology International, come as another pharmaceutical company, Gilead Sciences, announced pricing for its Covid-19 therapy, remdesivir. That drug, which was developed with at least $79 million in federal funding, will cost private insurers $520 for a single vial, hundreds of times its production cost, which researchers at the University of Liverpool have estimated at 93 cents per dose.

(Cont'd at link)


Link: The Trump Administration Is Waiving the Public’s Right to Affordable Coronavirus Treatments